Bain Capital Life Sciences Investors LLC Has $62.35 Million Stock Position in Disc Medicine, Inc. (NASDAQ:IRON)

Bain Capital Life Sciences Investors LLC decreased its holdings in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 45.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 983,500 shares of the company's stock after selling 812,235 shares during the period. Disc Medicine accounts for about 7.3% of Bain Capital Life Sciences Investors LLC's portfolio, making the stock its 4th biggest position. Bain Capital Life Sciences Investors LLC owned 3.30% of Disc Medicine worth $62,354,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. FMR LLC grew its stake in Disc Medicine by 358.7% in the fourth quarter. FMR LLC now owns 1,866,248 shares of the company's stock valued at $118,320,000 after acquiring an additional 1,459,434 shares during the period. Raymond James Financial Inc. bought a new stake in Disc Medicine during the 4th quarter valued at $5,579,000. Renaissance Technologies LLC bought a new stake in Disc Medicine during the 4th quarter valued at $5,479,000. Dimensional Fund Advisors LP lifted its stake in shares of Disc Medicine by 160.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 139,720 shares of the company's stock valued at $8,856,000 after buying an additional 86,154 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Disc Medicine by 17.6% during the third quarter. Geode Capital Management LLC now owns 474,719 shares of the company's stock valued at $23,333,000 after buying an additional 70,983 shares during the last quarter. Institutional investors and hedge funds own 83.70% of the company's stock.

Wall Street Analysts Forecast Growth

IRON has been the topic of several recent research reports. Wedbush reaffirmed an "outperform" rating and issued a $90.00 price target (up previously from $83.00) on shares of Disc Medicine in a research report on Tuesday, January 21st. HC Wainwright reaffirmed a "buy" rating and set a $118.00 target price on shares of Disc Medicine in a research report on Tuesday, January 21st. Morgan Stanley reissued an "overweight" rating and issued a $85.00 price target on shares of Disc Medicine in a research report on Friday, March 7th. Cantor Fitzgerald lifted their price objective on shares of Disc Medicine from $99.00 to $132.00 and gave the stock an "overweight" rating in a report on Tuesday, March 18th. Finally, TD Cowen began coverage on shares of Disc Medicine in a report on Thursday, February 27th. They issued a "buy" rating for the company. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $93.80.

Insider Buying and Selling at Disc Medicine

In related news, insider Rahul Khara sold 7,500 shares of the business's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $55.54, for a total value of $416,550.00. Following the sale, the insider now directly owns 14,035 shares in the company, valued at approximately $779,503.90. The trade was a 34.83 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Jean M. Franchi sold 3,136 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total transaction of $171,162.88. Following the sale, the chief financial officer now directly owns 69,530 shares in the company, valued at approximately $3,794,947.40. This trade represents a 4.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 361,690 shares of company stock worth $19,648,094 over the last ninety days. 4.24% of the stock is currently owned by company insiders.

Disc Medicine Stock Down 1.6 %

NASDAQ IRON traded down $0.75 during trading hours on Friday, reaching $45.42. 273,679 shares of the company were exchanged, compared to its average volume of 345,522. The stock has a market capitalization of $1.57 billion, a P/E ratio of -11.41 and a beta of 0.77. Disc Medicine, Inc. has a 1 year low of $25.64 and a 1 year high of $68.73. The business's 50 day simple moving average is $48.55 and its 200-day simple moving average is $55.02.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.08. As a group, sell-side analysts anticipate that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.